...
首页> 外文期刊>International Journal for Parasitology: Drugs and Drug Resistance >Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis
【24h】

Proteomic and functional analyses reveal pleiotropic action of the anti-tumoral compound NBDHEX in Giardia duodenalis

机译:蛋白质组学和功能分析揭示了在Giardia Duodenalis的抗肿瘤化合物NBDHEX的抗肿瘤作用

获取原文
           

摘要

Giardiasis, a parasitic diarrheal disease caused by Giardia duodenalis, affects one billion people worldwide. Treatment relies only on a restricted armamentarium of drugs. The disease burden and the increase in treatment failure highlight the need for novel, safe and well characterized drug options. The antitumoral compound NBDHEX is effective in vitro against Giardia trophozoites and inhibits glycerol-3-phosphate dehydrogenase. Aim of this work was to search for additional NBDHEX protein targets. The intrinsic NBDHEX fluorescence was exploited in a proteomic analysis to select and detect modified proteins in drug treated Giardia. In silico structural analysis, intracellular localization and functional assays were further performed to evaluate drug effects on the identified targets. A small subset of Giardia proteins was covalently bound to the drug at specific cysteine residues. These proteins include metabolic enzymes, e.g. thioredoxin reductase (gTrxR), as well as elongation factor 1B-@c (gEF1B@c), and structural proteins, e.g. @a-tubulin. We showed that NBDHEX in vitro binds to recombinant gEF1B@c and gTrxR, but only the last one could nitroreduce NBDHEX leading to drug modification of gTrxR catalytic cysteines, with concomitant disulphide reductase activity inhibition and NADPH oxidase activity upsurge. Our results indicate that NBDHEX reacts with multiple targets whose roles and/or functions are specifically hampered. In addition, NBDHEX is in turn converted to reactive intermediates extending its toxicity. The described NBDHEX pleiotropic action accounts for its antigiardial activity and encourages the use of this drug as a promising alternative for the future treatment of giardiasis.
机译:Giardiasis是由Giardia Duodenalis引起的寄生腹泻病,影响全世界十亿人。治疗仅依赖于药物的受限制的武器。疾病负担和治疗失败的增加突出了对新型,安全且表征的药物选择的需求。抗肿瘤化合物NBDHEX在体外对Giardia滋养本质有效,并抑制甘油-3-磷酸脱氢酶。这项工作的目的是寻找额外的NBDHEX蛋白靶标。在蛋白质组学分析中利用内在的NBDHEX荧光,以选择和检测药物治疗的Giardia中的改性蛋白质。在硅结构分析中,进一步进行细胞内定位和功能测定以评估对鉴定的靶标的药物影响。在特异性半胱氨酸残基的药物中与药物共价结合的小糖尿病蛋白。这些蛋白质包括代谢酶,例如代谢酶。硫昔林还原酶(GTRXR),以及伸长系数1B- @ C(GEF1B @ C)和结构蛋白,例如, @ a-timulin。我们展示了体外的NBDHEX与重组GEF1B @ C和GTRXR结合,但只有最后一个可以纳硝化NBDHEX,导致GTRXR催化性半胱氨酸的药物改性,伴随于二硫化物还原酶活性抑制和NADPH氧化酶活性升高。我们的结果表明,NBDHEX与多个目标作出反应,其角色和/或功能被专门妨碍。此外,NBDHEX又转化为延长其毒性的无反应中间体。所描述的NBDHEX抗性诉讼占其抗敏性活动,并鼓励使用这种药物作为未来治疗Giardiasis的有希望的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号